Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- (-) Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 97 Results
The Budget Cap Dilemma: Can You Reduce Spending and Preserve Patient Health?
National Pharmaceutical Council (NPC) hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Focus on Whole Person Quality Care When Implementing Budget Caps
The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…
Addressing Low-Value Care in the Time of COVID-19
The COVID-19 pandemic has had an enormous economic impact that is being felt across our communities, businesses and the overall health care system. It has placed a larger spotlight on the challenges…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
CMS Proposes Changes to Medicaid Best Price
CMS announced a proposal to lift some Medicaid best price restrictions, making it easier for commercial health insurers to enter into value-based payment arrangements with biopharmaceutical…
A Wish List for the Health Care Sector in 2020
NPC President and CEO Dan Leonard reflects on the health policy issues he hopes will be addressed in 2020.
Three Themes You’ll Take Away From “Health Spending: Moving From Theory to Action”
Health spending is increasing in the United States, but what steps are being taken to address this challenge? Join Health Affairs and the National Pharmaceutical Council (NPC) on September 11 for an…
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
NPC in Specialty Pharmacy Times: Creative Financing for Innovative, Curative Therapies
States are getting creative about how they can meet the health care needs of their citizens, especially when it comes to curative treatments for conditions with a high rate of prevalence. More…
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
NPC on Drug Pricing Analysis in Health Affairs Blog: The Limitations of Data
In response to a recent article published in Health Affairs, NPC Chief Science Officer Robert Dubois, MD, PhD, explores the potential inaccurate conclusions drawn from the study’s narrow analysis of…
What’s in a Number? It Matters in Health Policy Conversations
A study published in Value in Health by IQVIA and NPC takes a deeper dive on the data sources and methods behind a wide range of prescription medicine spending estimates cited by five different…
NPC in Chain Drug Review: Let’s Address Health System Improvements in 2019
In his latest column for Chain Drug Review, National Pharmaceutical Council President and Chief Executive Officer Dan Leonard looks deeper into 2019 and explores how we can take a more…